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What’s in an ACE: The Role of ACE2 in COVID-19’s Tissue Damaging Effects
Christian White
Dr. Oliver Oakley, Department of Biological Sciences

Coronavirus disease of 2019 (COVID-19) is the disease state caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current
pandemic. SARS-CoV-2 infects cells via the membrane bound form of angiotensin
converting enzyme 2 (ACE2). Aside from its role in viral entry, the role of ACE2 in the
morbidity and mortality of severe COVID-19 is often overlooked. ACE2 functions as a
member of the renin-angiotensin system (RAS) by cleaving the angiotensin II into
angiotensin (1-7). Angiotensin II increases inflammation, thrombosis, and inflammation,
whereas angiotensin (1-7) decreases these phenomena, making ACE2 an important
balancing agent. ACE2 is downregulated in severe COVID-19 by both viral entry, which
internalizes it, and the increased activity of “a disintegrin and metalloprotease 17”
(ADAM17), which cleaves it off the membrane, delocalizing it. A meta-analysis was
performed to demonstrate the striking resemblance between ACE2 downregulation and
severe COVID-19. Sources were examined according to organ, type of ACE2
downregulation, and symptom. The downregulation of ACE2 exhibits similar symptoms
in each organ for each pathology. RAS-based treatments of severe COVID-19 attempt to
counter the downregulation of ACE2 prevalent in the disease. The most promising is
human recombinant soluble ACE2 (hrsACE2; APN01), which both blocks viral entry and
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increases the functional ACE2 in the body. It is hoped that this study elucidates what is
known and highlights understudied aspects of ACE2 and its role in COVID-19.

keywords and phrases: coronavirus-disease of 2019, angiotensin converting enzyme 2,
severe acute respiratory syndrome coronavirus 2, inflammation, fibrosis, thrombosis,
ACE2 downregulation
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Introduction
History praises the military prowess of human conquerors, such as Alexander the
Great and Genghis Khan. However, disease has proven to be the most successful
conqueror of humankind. The dawn of civilization saw people group together in densely
populated communities, which made them much more vulnerable to infectious disease.1
Several of the most notable intersocietal achievements, including trade routes, wars, and
colonization, greatly enhanced the spread of diseases, and in return diseases greatly
shaped human populations and behavior.2,3 Cleaner living conditions were found to
decrease the transmission of disease, leading such progressions as organized sewer
systems, clean water sources, better sanitation availability, and the stigmatization and
measures against rodents.4,5 Quarantine, the isolation of individuals until they prove
healthy, has been widely used during pandemics and occasionally during immigration to
limit disease spread.4 Although society has learned many ways to mitigate the risk of
disease, pathogens occasionally bypass them and spread within and/or between human
populations.
There are many categories of pathogens, including bacteria, viruses, fungi,
protozoa, parasites, prions, and viroids. Of these, bacteria and viruses have caused the
most detrimental pandemics in history.2 In recent years, antibiotic drugs have become
widely available across the world, especially in developed nations.6 These drugs have
greatly reduced the severity of most bacterial diseases, reduced the likelihood of bacterial
pandemics, and raised life expectancy in developed nations.3,6 The main downside of
antibiotic use is that it selects for bacterial strains that develop antibiotic resistance
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mechanisms. Some of these strains have spread across the world, gaining notoriety in the
medical community.3,6,7 For example, methicillin-resistant Staphylococcus aureus
(MRSA) is a well-known strain that survives treatment with the antibiotic methicillin; it
most commonly infects hospital patients, and some strains of MRSA are also resistant to
other antibiotics.8,9 MRSA is just one of the growing set of “superbugs” that exhibit
multi-drug resistance (MDR).9 However, these antibiotic-resistant bacterial superbugs
typically only pose a danger to hospitalized and immunocompromised individuals.3
Besides these antibiotic resistant bacterial strains, most modern global pandemics are
viral, largely due to the lack of broad-spectrum antiviral drugs; antibiotics don’t affect
viruses, and antiviral drugs typically have too high of a specificity to be useful against
multiple viruses.3,10–12
Viruses are tiny infectious particles consisting of a protein capsid that surrounds
genetic material. With such a simplistic structure, viruses are windows into the very
origins of life.13 Viruses require outside machinery and materials to proliferate.14 Cellular
hosts fulfill this need, providing the ribosomes that will make viral proteins, the amino
acids that will form these proteins, and nucleotides to replicate the viral genome.15
Almost every cellular organism, whether prokaryote or eukaryote, has viruses that
specifically target it by exploiting unique cellular proteins and incorporating them as an
essential part of the viral life cycle.15 For bacteriophages, sometimes shortened to phages,
the hosts are bacteria; phages are model organisms for viruses and are the most abundant
organisms on the planet; they inject their genomes into bacteria from the outside in an
attempt to replicate by hijacking the bacteria’s resources.16 Another group of viruses
called virophages can infect other viruses, depending on both their helper-virus and its
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cellular host to complete their reproductive cycle.14 Regardless of the host, viruses utilize
cellular machinery to multiply at much higher rates than any cells.3 The high-speed viral
replication can contribute to carcinogenesis, the formation of cancer.17
Several reproduction strategies exist for viruses, depending on the type of genetic
material the virus uses: RNA or DNA, how many strands of genetic material it has:
single- or double-stranded, and whether it contains genetic exons directly encoding viral
proteins or requires a complementary strand: positive- or negative-sense, respectively.13
In general, viruses utilize two reproduction cycles, each having different consequences
for the host. In the lytic cycle, a virus infects a cell, reproduces in large enough numbers
to burst or lyse the host cell, then the new viruses search for a new host cell, leaving the
dead host cell behind.18 In the lysogenic cycle, a virus infects a cell and integrates its
genome into that of the host, leading to the production of more viruses.18 The lysogenic
cycle does not immediately kill the host cell, and can even provide it with evolutionary
advantages via “moron genes.”18,19 These beneficial genes often protect the host from
infection by other viruses, adding a symbiotic element to the virus-host relationship.19
All viruses, regardless of their reproductive strategies, must generate mRNA from
which the host cell ribosomes can create new viral proteins.13 All viruses copy their
genomes using host cell resources and encapsidate the produced genomes within the
protein capsids produced.13 DNA viruses use the host cell transcription enzymes to create
mRNA, and some are capable of being incorporated into the host cell genome.13 RNA
viruses either use RNA-dependent RNA-polymerase to both copy their genomes and
make enough mRNA to hijack most of the host cell ribosomes, or use reverse
transcriptase to make complementary DNA that is integrated into the host genome to be
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transcribed into mRNA; the latter RNA viruses are called retroviruses.13,15
Endogenization, the integration of viral genes into host genome, is a process that all
viruses of eukaryotes have potential for; retroviruses such as HIV utilize endogenization
as an essential part of their lifecycle.15
Due to endogenization and the incorporation of foreign DNA into their hosts,
viruses have shaped the genomes of modern species.15,20 At least 8% of the human
genome can be traced to retroviruses.20 Viruses can trade genes among themselves and
with their hosts in the process of horizontal gene transfer; they can also infect cells that
aren’t their optimal host in the process of zoonosis.15 These two processes, combined
with rapid reproduction, make the creation of new viruses not only possible but
expectable.
In general, RNA viruses are more likely to cause pandemics than DNA viruses
because they mutate more quickly, which results in higher variant quantity and the
potential for higher fitness.3 With complex modern trade and travel routes, the lack of
broad-spectrum antiviral drugs, the high rates of proliferation and mutation in viruses,
and the possibility of zoonosis, cross-species viral transmission due to the close
proximity of humans to animals, the modern world is particularly vulnerable to viral
pandemics. An RNA virus that recently evolved successfully exploited this vulnerability.
In December of 2019, a new sickness causing respiratory symptoms emerged in
people residing near an animal market in Wuhan, China.21 The virus responsible for the
pandemic is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
while the disease state it causes is termed coronavirus disease 2019 (COVID-19).22 The
number of COVID-19 cases grew exponentially, and the virus proved to spread more

5
quickly than influenza.21,22 In a matter of months, COVID-19 became an global
pandemic.21 There have been 153,505,262 reported cases of COVID-19 in 219 countries
(May 3, 2021).23 3,216,599 of these cases resulted in death (May 3, 2021).23
The virus spreads through the air in aqueous aerosols and droplets, which can
originate from the coughs and breathing of infected individuals, whether they are
symptomatic or not.24,25 Knowledge that SARS-CoV-2 spreads through the air has led to
the widespread use of protective masks, which decrease the intake and output of the virus
during breathing.25 Sanitation of surfaces can neutralize virus particles and also help limit
transmission.25 Another preventative measure involves testing sick people and travelers
for the disease.26,27 Quarantining those who test positive limits the amount of people they
can transmit the disease to, and in certain cases quarantining entire populations is
necessary to halt the spread.27
Symptoms of COVID-19 vary from person to person, but there are some well
documented patterns, with 3 standing out: mild, severe, and asymptomatic.24 Most
reported cases of COVID-19 are mild, though still unpleasant.28 In the first few days of
COVID-19, there are little to no symptoms.24 After an incubation period of 4-5 days,
symptoms may appear.24 Symptom experience varies between cases; common symptoms
include, but are not limited to, fever, cough, headache, fatigue, anosmia: loss of smell,
sore throat, myalgia: muscle soreness, seemingly chilblained red/purple “COVID toes,”
and gastrointestinal symptoms such as nausea, vomiting, and diarrhea.21,24,29 People with
certain pre-existing conditions, such as type 2 diabetes, cardiovascular disease (CVD),
chronic respiratory disease, and cancer, tend to have worse outcomes with COVID-19.30
More severe symptoms may begin to appear at an average of 5 to 8 days after initial
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symptoms, typically beginning with breathlessness, then ranging from respiratory
problems such as severe pneumonia, acute lung injury, and acute respiratory distress
syndrome (ARDS) to other problems, such as kidney damage, heart problems, and multiorgan failure.24,30 For severe COVID-19 cases, hospitalization is necessary. Treatments
include oxygen masks and, in more life-threatening cases, mechanical ventilators.30
Though many COVID-19 symptoms and nuances seem unrelated to each other from a
macroscopic level, they make much more sense by looking more closely how SARSCoV-2 interacts with its host.
SARS-CoV-2 enters cells through the membrane-bound form of an enzyme called
angiotensin-converting-enzyme 2 (ACE2), which is internalized during viral entry.31
Cells infected by SARS-CoV-2 lose functionality, leading to many of the minor
symptoms of COVID-19, such as anosmia.32 The relationship of SARS-CoV-2 and ACE2
goes beyond a simple virus-receptor interaction.33 Extensive infection by SARS-CoV-2,
as seen in severe cases of COVID-19 where the viral infection and/or immune response
occur at dangerous levels, reduces the amount of ACE2 in areas with a high viral
presence, having major consequences.33 ACE2 has anti-inflammatory, anti-fibrotic, and
anti-thrombotic effects as a part of the renin-angiotensin system (RAS).33 The
downregulation of ACE2 by SARS-CoV-2 in severe COVID-19 has inflammatory,
fibrotic, and thrombotic effects in the lungs, the cardiovascular system, and the kidneys.
We performed a meta-analysis to demonstrate the relationships between ACE2, COVID19, and organ failures. Examining SARS-CoV-2 and the RAS in close detail will help to
explain this relationship.
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SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that
causes coronavirus disease 2019 (COVID-19). Although SARS-CoV-2 is a novel
coronavirus, it follows many of the well-studied patterns seen in other coronaviruses.
Coronaviruses are enveloped in a lipid-protein envelope and contain positive sense
single-stranded RNA genomes.34 Their microscopic appearance is that of a membrane
surrounded by a crown, which is why they are called coronaviruses: corona is Latin for
crown.35 Coronavirus genomes are around 30,000 base pairs long, making them the
largest RNA viruses known.35 SARS-CoV-2 has about 29,900 bases in its genome.36 The
first two thirds of coronavirus genomes encode a polyprotein that is proteolytically
cleaved into smaller proteins with virus-creating functions, while the final third encodes
structural proteins that protect the genome and facilitate entry via a host cell receptor.34
The coronavirus family is divided into four genera: alpha and beta coronaviruses
infect primarily mammals, gamma coronaviruses infect primarily birds, and delta
coronaviruses can infect both mammals and birds.35,37 Though there are many viruses in
the coronavirus family, only seven are known to infect humans: HKU1, NL63, OC43,
229E, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome
coronavirus (SARS-CoV), and SARS-CoV-2.37,38 HKU1, NL63, OC43, and 229E each
cause mild symptoms consistent with the common cold.37 On the other hand, SARS-CoV,
MERS, and SARS-CoV-2 have higher infection and mortality rates.37
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Coronaviruses arise in humans through zoonosis, a host-species-switching process
where viruses from one animal species infect another animal, typically from genome
mutations and close physical proximity that select for this change.39,40 To confidently
identify the immediate ancestor of a virus, another virus with nearly identical genome
must be identified (>99% similarity).41 Bats and birds are a major reservoir for
coronaviruses, but they are not the only animals involved in transferring coronaviruses to
humans.40 It is widely accepted that bat coronaviruses gave rise to MERS, SARS-CoV,
and now SARS-CoV-2.36,42 However, with MERS and SARS-CoV, intermediate hosts
were also involved that accepted bat coronaviruses and gave rise to human
coronaviruses.39,42 For MERS, the intermediate host was the dromedary camel.39 For
SARS-CoV, the intermediate host was the civet cat.36,39 The previous hosts for NL63 and
229E were bats.39 Bovine and rodent coronaviruses gave rise to OC43 and HKU1,
respectively.39,43 The zoonotic origins of SARS-CoV-2 are not yet fully understood, but
bats are the most likely source, with the bat coronavirus RaTG13, found in China, having
a 96.21% genome similarity to SARS-CoV-2.41,44 Some scientists are skeptical of
RaTG13’s legitimacy, but other scientists have found similar strains of bat coronaviruses
in nearby countries such as Thailand.41,44 Climate change may have affected bat
population density in Southeastern Asia so as to promote coronavirus zoonoses.45
Pangolins are also being considered as potential zoonotic sources, as certain pangolin
coronaviruses have similar receptor-binding domains on their spike proteins to that of
SARS-CoV-2.41,44 Previously discovered human coronaviruses are not suspected of
mutating into SARS-CoV-2, as they are too dissimilar. SARS-CoV is the most similar,
sharing only 79.5% genomic homology with SARS-CoV-2.36 MERS has only about 50%
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genomic homology with SARS-CoV-2.36 Identifying the zoonotic source of SARS-CoV2 is crucial to preventing similar catastrophic zoonoses in the future.
Coronaviruses share several structural proteins that differ in sequence but not
function. The general structure for SARS-CoV-2 is shown in Figure 1. Membrane (M)
proteins organize as 2-dimensional lattices to form most of the outer virion, or virus
structure, both initially as a frame to build the rest of the virion and in the completed
virion.46 Envelope (E) proteins are also part of the external virion structure; they
oligomerize-combine with other E proteins-to form pores that may disrupt ion gradients
within the endoplasmic reticulum or the Golgi bodies, leading to the exocytosis of the
virion.46 When both M and E proteins are produced, spherical structures are produced in
combination with the endoplasmic reticulum membrane.46

Figure 1: SARS-CoV-2 structural diagram. The nucleocapsid protein and RNA lie within
the virus. The outer envelope contains envelope proteins, spike proteins, membrane
proteins, and hemagglutinin esterase. Image from Florindo et al., 2020.47
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The third structural protein on coronaviruses is the nucleocapsid (N) protein. N
proteins are highly expressed in coronaviruses and associate with their RNA within the
capsid through electrostatic interactions.46 N proteins aid in viral entry, influencing
cellular processes, and facilitating RNA conformational shifts as RNA chaperones.46,48
They can even inhibit certain immune responses such as interferon production, increasing
susceptibility to the virus.46
The fourth and largest structural protein all coronaviruses express is the spike (S)
glycoprotein.48 The spike is highly glycosylated and initiates viral entry into cells.48 The
spike is a homotrimer with two subunits.48 The S1 subunit contains a receptor-binding
domain (RBD) that initiates entry upon binding a host receptor.48 The S1 subunit can
have an active “up” conformation or an inactive “down” conformation.46 After binding a
host receptor, the S1 subunit dissociates from the S2 subunit.46 The S2 subunit then
facilitates entry by either fusion or endocytosis, depending on the specific coronavirus
and/or the host’s characteristics.49 The spike protein extends the furthest away from the
center of the virus, and is thus the optimum target for adaptive immunity, whether by
vaccination or direct exposure to SARS-CoV-2. It is also the characteristic that gives rise
to the crown-like appearance of coronaviruses, as seen in Figure 2. Although each
coronavirus expresses spike proteins, their respective spikes can have different targets.
The MERS spike targets dipeptidyl peptidase 4.35 229E targets aminopeptidase N.50
OC43 and HKU1 spikes bind to sugars called 9-O-acetylated sialic acids.35,51 NL63,
SARS-CoV, and SARS-CoV-2 all bind membrane-bound angiotensin converting enzyme
2 (ACE2), despite NL63 having a much different spike protein from SARS-CoV and
SARS-CoV-2.35,52
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Figure 2: SARS-CoV-2 particles isolated from a patient, viewed with transition electron
microscopy.53 Image captured and colored by the National Institute of Allergy and
Infectious Disease (NIAID) Integrated Research Facility (IRF) in Fort Detrick,
Maryland.53
Some coronaviruses express a fifth structural protein called hemagglutinin
esterase (HE). HE is only expressed by beta coronaviruses, which for humans include
OC43, HKU1, MERS, SARS-CoV, and SARS-CoV-2.48 It is another component of the
viral envelope for these viruses. HE is thought to have receptor destroying properties in
OC43 and HKU1, but it is understudied, especially in the case of SARS-CoV-2.43,48
Although SARS-CoV-2 follows the structural patterns outlined, it also has some
unique features not seen in other human coronaviruses. Although the genomes of the
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human coronaviruses differ among all the proteins that they encode, the spike protein is
where these differences stand out. The SARS-CoV-2 spike protein RBD binds ACE2
with higher affinity than the SARS-CoV spike RBD, despite both binding to the same
region on ACE2.38,54 Also, certain strains of SARS-CoV-2 have mutations in the spike
and its RBD that increase affinity for ACE2 beyond the original Wuhan strain.55 An
example of this acquired advantage via spike mutation is the strain first identified in
South Africa (lineage B.1.351).55 The differing affinities for ACE2 among SARS-CoV,
SARS-CoV-2, and mutant SARS-CoV-2 spike proteins are due to key residue differences
in the RBDs of these spike proteins.38,55 Another unique feature of the SARS-CoV-2
spike protein is the presence of a furin cleavage site, an RRAR insertion where the
SARS-CoV spike has just an R, between the S1 and S2 subunits.38 The presence of a
furin cleavage site is associated with higher infectivity and a larger host range; the furin
cleavage site allows the S1 and S2 subunits to separate upon being acted on by a
compatible protease like furin, after which the S1 subunits float away and the S2 trimer
facilitates fusion.38 For SARS-CoV-2, the proteases that work the best at facilitating this
cleavage are TMPRSS2, a cell surface serine protease, and lysosomal proteases such as
cathepsin.56 These same proteases also help activate fusion in SARS-CoV by activating
its spike, although the furin cleavage site is absent.56 A recent study that removed the
furin cleavage site on SARS-CoV-2 found that pathogenesis was reduced.57 Interestingly,
exposure to SARS-CoV-2 with this furin cleavage site removal provided adequate
immunity to fight wild-type SARS-CoV-2.57 Thus, the SARS-CoV-2 spike binds ACE2
with high affinity at the RBD and has a furin cleavage site, both of which contribute to a
higher infectivity than that seen in SARS-CoV.
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The entry mechanism of SARS-CoV-2 is becoming highly researched but remains
contentious in certain aspects; still, enough is known for a general outline of the process.
The infection cycle of SARS-CoV-2 begins when its RBD on S1 binds to membranebound ACE2.56 Upon this binding, depending on the presence or absence of the
TMPRSS2, two entry pathways exist (Figure 3).49,58 If TMPRSS2 is present on the cell
surface, it cleaves the spike protein at the S1/S2 border.49 S1 dissociates from the virus,
floating away in the extracellular fluid likely with its receptor, ACE2.54,56 The S2 subunit
facilitates membrane fusion with the cell, after which the viral RNA is released into the
cytosol.49 It is unknown whether this membrane fusion creates a temporary pore or a
permanent and complete fusion.49 Since TMPRSS2 expression is higher in men, as its
expression depends on androgen levels, excess in this entry pathway potentially
contributes to the differing severities of COVID-19 between the sexes.59 Alternatively, if
TMPRSS2 is not present, endocytosis occurs.49 This typically but not necessarily
involves clathrin, an endocytic protein.49 Once the virus is taken into an endosome, the
endosome travels to and fuses with a lysosome.49 Within this lysosome, proteases such as
cathepsin and furin facilitate the fusion event by cleaving the S1/S2 cleavage site,
releasing the S1 subunit and ACE2 into the lysosome.49,60 S2 then facilitates the fusion,
and the viral RNA is released into the cytosol.49 Once the viral RNA is released into the
cytosol, the two pathways converge.
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Figure 3: SARS-CoV-2 entry occurs by either endocytosis or direct fusion. Diagram
modified from Mahmoud et al., 2020.58
Once in the cytosol, the viral RNA travels to and binds the host ribosomes and
translation occurs, producing proteins and polyproteins that divide into several functional
proteins that help in the virus-making process.61 Perhaps the most important of these
functional proteins is RNA-dependent RNA polymerase (NSP12), which copies and
greatly amplifies the amount of viral RNA within the cell.61 The RNA in the cell
accumulates, and ribosomes start making lots of viral structural proteins. The M, S, E, N,
and HE proteins form virions, many of which successfully contain a viral RNA strand.
The completed viruses are then ready to leave the cell. There are two main mechanisms
for leaving the cell. Extrusion, or budding, is a form of exocytosis in which the virus is
neatly released to the interstitium.62 Lysis occurs when the cell builds so many viruses
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that the pressure bursts the cell, releasing all of the viruses and killing the cell. Regardless
of the way the viruses are released, they immediately search for new cells to infect by
blindly extending and retracting their new spike proteins, relying on Brownian motion to
connect them with ACE2. But ACE2 is more than just a receptor for SARS-CoV-2.63 Its
function is critical, and when its levels are insufficient, the effects are devastating.
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Renin-Angiotensin System
Angiotensin converting enzyme 2 (ACE2) is involved in a complex pathway
called the renin-angiotensin system (RAS). The RAS governs many aspects of the body’s
organs and cardiovascular system, and research continues to reveal new functions and
mechanisms of the RAS.64 The first RAS component was discovered in 1898 by Robert
Tigerstedt and his student Per Bergman.64,65 They noticed that a molecule from the renal
cortex caused blood pressure to be raised, and called that molecule renin.64,65 Renin was
forgotten about until its rediscovery the 1930’s, and by 1970’s many more RAS
components were identified.64
Around that time, the RAS was considered to consist of a sequential string of
reactions occurring by enzymes from various organs in the circulation.64 This classical
RAS pathway goes as follows: renin from the kidneys cleaves angiotensinogen from the
liver into angiotensin I, which is then turned into angiotensinogen II by angiotensinconverting enzyme (ACE) mostly in the lungs.64,66 The angiotensin II then causes the
release of the hormone aldosterone from the adrenal cortex, and blood pressure is
raised.64,66 Although all of this is true, the RAS has now been proven to be much more
extensive in its participants, its functionally, and where it occurs in the body.64
One popular modern model of the RAS focuses on the existence of two connected
pathways, the “classical pathway” and the “alternative pathway,” that work in opposition
to each other (Figure 4).67 Although more complex models exist that outline more
reactants, receptors, and effects, the dual pathway model is adequate to describe the
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physiological role of ACE2.67 The classical pathway consists of the aforementioned
linear pathway wherein angiotensinogen is converted into angiotensin I by renin, and
angiotensin I is converted to angiotensin II by ACE.64,66,67 The alternative pathway was
discovered more recently; its key enzyme ACE2 was discovered in 2000.33 In this
pathway, angiotensin I and angiotensin II are converted to angiotensin (1-9) and
angiotensin (1-7), respectively, by ACE2.33,67 The effects of these two pathways are
opposite: The classical pathway promotes vasoconstriction, fibrosis, inflammation,
coagulation, edema, oxidative stress, and the water reabsorption hormones aldosterone
and antidiuretic hormone (ADH).33,67,68 The alternative pathway, on the other hand, has
vasodilative, antifibrotic, anti-inflammatory, anticoagulative, anti-edemic, antioxidant,
and natriuretic effects.33,67,68
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Figure 4: The dual pathway model of the RAS. Made with information from Ocaranza et
al., 2020, Verdecchia et al., 2020, and Te Riet et al., 2015.33,67,68
RAS enzymes have often been associated with certain organs and assumed to be
irrelevant in others.64 Although there are expression differences for RAS enzymes for
each organ, there is enough expression to generate a “local RAS” for each organ and
blood vessel.64,69 When the whole body’s RAS or the local RAS for a tissue are
unbalanced, pathologies result.67–70
The RAS begins with the liver, which produces and secretes most of the body’s
angiotensinogen.71 Interestingly, angiotensinogen is also produced in various other
organs, including the kidneys, heart, and even the brain.71–73 Angiotensinogen is the
precursor to the angiotensin peptides, and thus both RAS pathways depend on it to elicit
changes.67,72
Renin is an aspartate protease that converts angiotensinogen into usable
angiotensin I.74 The major source of renin in the body are the juxtaglomerular cells of the
kidney.74 However, prorenin, the renin precursor, is expressed throughout the body.74
Prorenin is also present in the circulation in levels much higher than renin.74 This
prorenin is inactive, but can give rise to functional renin.74
Angiotensin I is a short peptide involved in both the classical and the alternative
RAS pathway.67 Angiotensin I is not known to bind receptors directly, but it is a
precursor for multiple receptor ligands.67 The levels of ACE and ACE2 determine what it
becomes.33
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Angiotensin converting enzyme (ACE) is an integral component of both the
classical and alternative RAS pathways.67 It facilitates the conversion of angiotensin I to
angiotensin II as well as the conversion of angiotensin (1-9) to angiotensin (1-7).67 ACE
is originally expressed on cell membranes, but can be cleaved to a soluble form that is
still enzymatically active.75 Many tissues express ACE, including but not limited to the
lungs, heart, kidneys, and even certain immune cells like macrophages.70
Angiotensin converting enzyme 2 (ACE2) is the gateway for commitment to the
alternative RAS pathway.67 It converts angiotensin I into angiotensin (1-9) and
angiotensin II into angiotensin (1-7).67 This causes a decrease in the effects of angiotensin
II and an increase in the effects of angiotensin (1-7), both of which will be discussed
shortly. ACE2 shares about a 42% sequence identity to ACE.75 ACE2 also is initially
membrane bound, with the potential to be cleaved into a soluble but still active form.75,76
A disintegrin and metalloprotease 17 (ADAM17) is one membrane enzyme capable of
performing this cleavage.33,76 ACE2 is expressed throughout the body, especially in the
lungs, heart, kidneys, liver, colon, testes, and blood vessels.33,75,76 Several polymorphisms
of ACE2 exist in populations, with catalytic efficiency being reduced in some of them.77
ACE2 expression is often increased in damaged organs as an attempt to facilitate
healing.78 Often a higher soluble ACE2 level is associated with a lower membrane-bound
ACE2 level in organ tissues, and thus indicates a RAS imbalance for those organs in
favor of the classical RAS pathway.79,80 The local ratios of ACE and ACE2 are important
in determining which RAS pathway that tissues favor.76,81
Angiotensin II is the main facilitator of the classical RAS pathway. It acts on the
angiotensin II type 1 receptor (AT1R) to elicit the vasoconstrictive, fibrotic,
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inflammatory, coagulative, oxidative, and water-reabsorbing effects of the classical
RAS.33,67 Alternatively, it can bind to other receptors such as the angiotensin II type 2
receptor (AT2R) and the angiotensin II type 4 receptor (AT4R) to cause similar effects to
those of the alternative RAS.33,67,68 However, the effects of AT2R and AT4R are not
typically pronounced enough to balance the effects of angiotensin II has when binding
the AT1R, making high levels of angiotensin II damaging.33
Angiotensin (1-9) is formed from angiotensin I by ACE2.33,67 It is capable of
binding to the AT2R, countering the effects of the classical RAS.67 It is also the precursor
to angiotensin (1-7), the main facilitator of the alternative pathway.33,67 This conversion is
done by ACE.33,67
Angiotensin (1-7) is the final product in the alternative RAS.33,67 It binds to the
Mas receptor (MasR) to elicit vasodilative, antifibrotic, anti-inflammatory,
anticoagulative, anti-edemic, antioxidant, and natriuretic effects.33,67–69 Angiotensin (1-7)
is also associated with slowing down aging and has healing effects on organs.69,82
In the context of COVID-19, it is easy to perceive ACE2 as the receptor for
SARS-CoV-2 without considering the function of ACE2 in the RAS. Several disease
states are associated with RAS imbalances, and severe COVID-19 matches the symptoms
of these imbalances. Although the direct relationship between severe COVID-19 and
RAS imbalances are largely understudied, viewing COVID-19 from the perspective of
the RAS elucidates why certain symptoms are experienced in ways that a traditional viral
infection perspective fails.
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ACE2 Downregulation
Most ACE2 in the body is in the membrane-bound form, but some soluble ACE2
is also detectable in healthy individuals. ACE2 downregulation occurs when subnormal
levels of membrane bound ACE2 are present in a tissue. These downregulations can be
local, affecting only one tissue through a local RAS, or systemic, affecting the whole
body by pervasive downregulation. Recent studies have indicated ACE2 downregulation
to be a major factor in several pathologies, and new research is consistently broadening
the list of disorders that ACE2 downregulation plays a role in.
Several pathologies are associated with less membrane bound ACE2 presence.
The most notable examples are hypertension, type 2 diabetes mellitus, and cardiovascular
disease.83,84 Some others include organ fibrosis, thromboembolisms, acute respiratory
distress syndrome (ARDS), and even certain cancers.33,84–86 Patients with each of these
conditions tend to have a higher morbidity during COVID-19.30,33,87,88 Often, the
downregulation of membrane ACE2 in tissues is accompanied by an increase in serum
ACE2.79,84 This is also often seen in severe cases of COVID-19.89 This is likely due to
increased ADAM17 activity, which facilitates this change.79,84
In addition to the association of lower membrane bound ACE2 levels with these
disorders, ACE2 levels also vary in healthy individuals according to several controllable
and uncontrollable factors.84 Smoking increases ACE2 expression in the lungs, likely as
an attempt to heal the damages done by the inhaled toxins.84 Diets high in salt also
increase ACE2 expression and activity to decrease the amount of sodium in the blood by
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reducing the aldosterone production and secretion that is caused by angiotensin II, thus
promoting natriuresis.84 Glucose and fat-rich diets reduce ACE2 levels.33,84 ACE2 levels
decrease with age, which is likely due to increased ADAM17 activity, as serum ACE2
levels increase with age.33,79,84 This age effect is sex-dependent, with males losing
membrane ACE2 sooner in life than females.79,84 One theory explains this sex-effect as a
being independent to the amount of sex chromosomes present, despite ACE2 being
present on the X chromosome; however, one study found the level of ACE2 expression in
mouse kidneys to be dependent on estrogen levels, which are higher in females.90
Several mechanisms have been proposed for the downregulation of ACE2 in
COVID-19, but this downregulation is largely understudied. This is perhaps due to the
overshadowing of ACE2’s role in the RAS by its role in the entry of SARS-CoV-2.33
Other mechanisms that may play a part are barely being considered, if at all. Table 1
summarizes four mechanisms that will be discussed shortly. It is most likely true that a
combination of the following mechanisms, rather than just one, explain the
downregulation of ACE2 seen in severe COVID-19.
Mechanism of ACE2 Downregulation
Effect on ACE2
in Severe COVID-19
Entry of SARS-CoV-2

Removal from cell surface; internalization
Cleavage; less on cell surface, more in

Increased ADAM17 activity
serum
HE activity?

Destruction

Genetic Downregulation by COVID-19?

Less production
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Table 1: Proposed mechanisms of ACE2 downregulation in severe COVID-19. Each of
these mechanisms would reduce the amount of ACE2 on the tissues dealing with
infection. The first two mechanisms are most likely correct. The last two mechanisms are
largely unproven and understudied in the case of SARS-CoV-2 and COVID-19, which is
why there is a question mark after them.
The two roles of ACE2 in COVID-19 as the receptor for SARS-CoV-2 and a
healing component for the organs damaged are not mutually exclusive. When SARSCoV-2 enters the cell, it internalizes ACE2 in a way that prevents its return to the cell
surface.31,78 When lots of viruses are internalized, as in severe cases of COVID-19,
enough ACE2 internalization occurs to effectively downregulate local ACE2 levels,
whichever tissue the extensive infection is occurring in.31,78 Higher TMPRSS2 expression
allows for more SARS-CoV-2 and ACE2 to be internalized, exacerbating this mechanism
of downregulation.84
Another way that severe COVID-19 likely downregulates ACE2 is by increasing
the activity of ADAM17, which sheds the membrane bound ACE2.31 Although this leads
to higher soluble ACE2 levels in the serum, it is important to realize that serum ACE2 is
no longer exclusively present at its source tissue, and thus excessive ADAM17 activity
can deprive an organ of its ACE2.84 ADAM17 activity is increased by the presence of
inflammatory cytokines.84 Severe COVID-19 patients often experience cytokine storms,
ubiquitous inflammatory cytokine presence that likely increase ADAM17 activity.84,91
The high levels of soluble ACE2 often found in severe COVID-19 patient serum are
consistent with this mechanism.92
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COVID-19 may involve other mechanisms of ACE2 downregulation as well.
Hemagglutinin-esterase (HE) is present on SARS-CoV-2, as described in the previous
section.43,48 HE has been known to degrade entry receptors in other viruses such as
influenza.43,48 The effects of the HE of SARS-CoV-2 on ACE2 are largely unknown, but
perhaps degradation occurs that could contribute to ACE2 downregulation.
Another understudied mechanism is genetic downregulation, wherein less ACE2
mRNA is transcribed. Studies showed that infection with SARS-CoV, which also infects
via ACE2, led to less ACE2 mRNA transcription.93 If the same phenomenon occurs with
SARS-CoV-2, this would reduce the amount of ACE2 present on organs experiencing
this effect.
Different ACE2 polymorphisms also have differing efficiencies.77 Although this
is not downregulation, mutant ACE2 can have the same effects as ACE2 downregulation.
Some less efficient varieties of ACE2 are likely associated with risks for more severe
COVID-19.77 Another consideration with ACE2 polymorphisms is that some likely have
a higher affinity for the SARS-CoV-2 spike than others.94
Regardless of the circumstances behind ACE2 downregulation, it presents with a
clear pattern of symptoms. Organs deficient in ACE2 experience exaggerated classical
RAS effects from angiotensin II, leading to inflammation, thromboembolisms, and
suboptimal healing that often includes fibrosis.31,33,78,84 These effects are well
documented in ACE2 knockout models, ACE2 deficient disease states, and severe
COVID-19. The following meta-analysis illustrates this correlation.
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Inflammation
Inflammation is the process wherein white blood cells (WBCs) infiltrate organ
tissues to counter infectious agents that may be present. Once these WBCs enter the
tissues, they secrete harmful chemicals to kill the pathogen.95 Inflammation is initiated
when an organ’s resident macrophages secrete cytokines and chemokines that attract
circulating cells of innate immunity, such as monocytes and neutrophils.95,96
Inflammation continues until the infection is destroyed. If the innate immune system is
insufficient for several days, the adaptive immune system attempts to stop the infection.
The adaptive immune system, especially its T cells, can also promote inflammation, and
can deal collateral damage to healthy tissue cells.96 In the effort to contain an infection,
inflammation also generates cell-damaging reactive oxygen species (ROS).97 The RAS
plays a major role in inflammation both for innate and adaptive immunity.98 When
angiotensin II binds the AT1R on immune cells, a transcription factor called nuclear
factor κB (NF-κB) is activated and causes the transcription of pro-inflammatory genes
encoding cytokines and chemokines (Figure 5).95,98,99
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Figure 5: NF-κB expression in immune cells causes inflammation. The main cells that
facilitate this inflammation are macrophages, neutrophils, and, later during the infection,
T cells. Diagram made by Liu et al., 2017.95
Though inflammation is important for defending tissues from being compromised
by foreign invaders, it can also occur when the foreign object is harmless, thus causing
more damage than no response at all would have.100 Allergies are a good example of
inflammation in response to a nonharmful stimulus.100 Inflammation can also be
damaging when it occurs at a much higher level than an infection requires to be
quelled.100 In these ironic instances, efforts to save an organ from an infection sacrifice
the organ or even the organism to do so.100 With allergies, this overreaction is called
anaphylaxis and is mediated by cytokines.100 The RAS can be a major player in this
aspect of inflammation as well.101 When more angiotensin II is present, inflammation
occurs to a larger degree, because of its pro-inflammatory effects on leukocytes,
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endothelial cells, and vascular smooth muscle.101 Since ACE2 downregulation leads to an
accumulation of angiotensin II, it also causes increased inflammation.97
Severe cases of COVID-19 often exhibit excessive inflammation.102,103 This
inflammation can be localized or ubiquitous.103 Potential causes of ubiquitous
inflammation in COVID-19 include macrophage activation syndrome (MAS, also called
“cytokine storm”) and T cell lymphopenia, among others.103 With MAS, inflammatory
cytokines reach a high enough level to cause monocytes to systemically enter tissues and
promote more inflammation, severely harming tissues all over the body.103 In T-cell
lymphopenia, severe infection by SARS-CoV-2 exhausts and depletes T cells, likely
leading to an imbalance in adaptive and innate immunity that exacerbates the cytokine
storm.103,104 The high level of inflammation can cause acute respiratory distress syndrome
(ARDS), a potentially fatal complication in the lungs (Figure 6 and Figure 7).102,103,105
They can also contribute to life-threatening kidney injuries in the renal corpuscle and
tubules (Figure 8).106
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Figure 6: Inflammation of the lungs in severe COVID-19. The alveoli lose their
squamous features and macrophages are present in the tissue and the alveolar space.
Image from Tian et al., 2020.102
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Figure 7: Lungs from a patient who died of COVID-19. A is the macroscopic
appearance. B shows the histopathology: the endothelium is inflamed at several points.
Image from Ackermann et al., 2020.105

Figure 8: Autopsy of a severe COVID-19 patient reveals necrosis and neutrophil
infiltration in the tubules of the kidney. Image from Santoriello et al., 2020.106
Similar levels of inflammation are also seen in ACE2 knockout models and other
ACE2 deficient disease states. Research on the relationship between ACE2 and
inflammation has surged since the start of the pandemic (Figure 9). The following metaanalysis sorts a sample of sources reporting inflammation by their organ in these three
pathological states (Table 2). Sources were obtained from PubMed and Google Scholar
by searching “ACE2 knockout inflammation [organ],” “ACE2 inflammation [organ],” or
“COVID inflammation [organ].” The results were then screened according to their useful
insights, experimental results, and images. Sources that had no input relevant to this study
were not included. Three organs, the lungs, heart, and kidneys, were considered, but the
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effects of ACE2 downregulation are felt by any tissue with this downregulation. Each
bold number indicates the number of sources found that indicated an increase in
inflammation. No sources associated ACE2 deficiency with decreasing inflammation.

Figure 9: PubMed results for “ACE2 Inflammation” by year. Research in this area was
slowly increasing until 2019, which saw a large increase in the amount of research in this
area due to COVID-19. Data collected on May 3, 2021.
Organ

ACE2 Knockout

Low ACE2

Severe COVID-19

5

6

11

Lungs
107–111

*

33,63,112–115

*

88,105,112,113,115–121

*

9
3

9
113,115,121,127,128,130,132–

Kidneys
122–124

*

63,115,125–131

*
134

Cardiovascular

2
10

System

135,136

*

9

*

31
63,76,113–115,130,137–

140

*

31,113,115,121,130,138,141–

143

*

Table 2: Meta-analysis data on the increase in inflammation reported for ACE2 knockout
models, low ACE2 presence in tissues, and severe COVID-19. Each of these pathological
conditions promote inflammation in each of the organs examined. *The smaller numbers
correspond to the sources.
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Coagulopathy
Coagulopathies are pathologies regarding excessive or insufficient blood clotting.
In healthy individuals, coagulation occurs to seal wounds, preserve fluids, and prevent
any microbes present from entering circulation. The formation of a blood clot occurs
through the actions of the coagulation cascade (Figure 10).144–146 An injury exposes
tissue factor and collagen, which bind to clotting factors and platelets.147,148 Factor X is
converted to factor Xa by one of two pathways, depending on whether tissue factor or
collagen was detected.144 Factor Xa then converts prothrombin to thrombin.144–146 The
thrombin subsequently converts fibrinogen into fibrin, which acts like a net, covering the
wound and trapping all cells present in a scab, including red blood cells, platelets, and
any bacteria that is present.144,145 Coagulation can also occur for internal bleeding, in
which endothelial tissue integrity is compromised, through the same coagulation cascade;
this internal coagulation creates a thrombus.138,144 Blood clots, specifically the fibrin nets
holding them together, are eventually broken down by plasmin, the active form of
plasminogen.149 Angiotensin II activates platelets to coagulate and discourages
anticoagulative actions from endothelial cells by causing the secretion of plasminogen
activator-inhibitor type 1.150 ACE2 is highly expressed in endothelial cells and plays a
protective role for them thus countering the formation of thrombi.150 Also, platelets have
a Mas receptor for Angiotensin (1-7), which upon binding it promotes production of
nitric oxide (NO), which has anticoagulative properties.150
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Figure 10: The coagulation cascade. Angiotensin II promotes coagulation by
encouraging platelet activation and causing endothelial cells to inhibit circulating
plasminogen. ACE2 decreases coagulation by reducing angiotensin II levels and
inactivating platelets by increasing angiotensin (1-7) levels, which stimulates the platelets
to produce NO. Diagram from Overbey and Jones, 2014.146
Although blood clotting is crucial to survival, coagulopathies can reduce the
fitness advantage it provides. Thrombosis describes when blood clots form in the absence
of injury, blocking blood flow to the cells that need the nutrients and oxygen from the
blood.151,152 The blockage of oxygen access leads to ischemia and parenchymal death,
and potentially fibrosis.152 Another potential complication of thromboses are embolisms,
which occur when a thrombosis is formed in one tissue, often leg veins, then dislodges
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and travels through the blood stream to another tissue, similarly blocking blood flow to
the new tissue.151 The word thromboembolism describes both phenomena.151
Thromboembolism can result in tissue death, such as that seen in acute lung injury
(ALI).145
Tiny thromboembolisms are extremely common in severe cases of COVID19.105,116,117 Microthrombi can also contribute to respiratory failure and ARDS, which can
occur with or be independent of severe COVID-19.105 Microthrombi in the lungs of a
casualty of severe COVID-19 are shown in Figure 11.105 Several autopsies of severe
COVID-19 patients have also found excessive coagulation in the kidneys (Figure 12).106

Figure 11: Inflammation with microthrombi in the lung tissue of a patient who died of
severe COVID-19. Blood is also visible in the alveolar space. The arrowheads indicate
the clots. Image from Ackermann et al., 2020.105
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Figure 12: Autopsy of a severe COVID-19 patient reveals capillary congestion and a
large thrombus in the glomerulus of a kidney. The arrow indicates the large thrombus.
Image modified from Santoriello et al., 2020.106
A high frequency of thromboembolisms also manifests in ACE2 knockouts and
other ACE2 deficient disease states.150 Research in this area has recently surged (Figure
13). The following meta-analysis sorts a sample of sources reporting thrombosis by their
organ in these three pathological states (Table 3). Each bold number indicates the
number of sources found that mentioned an increase in thrombus formation. Sources
were obtained from PubMed and Google Scholar by searching “ACE2 knockout
thrombosis [organ],” “ACE2 thrombosis [organ],” or “COVID thrombosis [organ].” The
results were then screened according to their useful insights, experimental results, and
images. Sources that had no input relevant to this study were not included. Three organs,
the lungs, heart, and kidneys, were considered, but the effects of ACE2 downregulation
are felt by any tissue with this downregulation, especially considering the potential
mobility of thrombi. No sources associated ACE2 deficiency with less thrombosis. No
ACE2 knockout studies were found to examine the relationship between ACE2 and
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thrombosis; however, this area of ACE2 is largely understudied compared to
inflammation and fibrosis. The low ACE2 studies and COVID-19 studies examined both
indicated more thrombosis.

Figure 13: PubMed results for “ACE2 Thrombosis” by year. Research in this area was
low until 2019, which saw a large increase in the amount of research due to COVID-19.
Data collected on May 3, 2021.

ACE2
Organ

Low ACE2

Severe COVID-19

Knockout
11
8
Lungs

105,112,113,115–

0
33,63,112–115,150,153

*
118,120,121,154,155

4
Kidneys

*

9

0
63,115,127,130

*

113,115,121,127,130,132,134,154,156

*

37
8
Cardiovascular

8
0

33,63,113–
113,115,121,130,138,141,142,157

System
115,130,138,150

*

*

Table 3: Meta-analysis data on the increase in thrombosis reported for ACE2 knockout
models, low ACE2 presence in tissues, and severe COVID-19. Low ACE2 and severe
COVID-19 both exhibit more thrombosis. ACE2 knockout studies did not examine
thrombosis; no increase, decrease, or normal thrombosis rates were discussed by these
studies. Low ACE2 levels and severe COVID-19 both report thrombosis. *The smaller
numbers correspond to the sources.

38

Fibrosis
Scarring occurs to preserve the integrity of tissues. Fibrosis is simply the
pathological scarring of internal organs.158 Fibrosis and scarring in general are facilitated
by cells called myofibroblasts, which differentiate from fibroblasts.158 Myofibroblasts
migrate to sites of tissue injury to secrete extracellular matrix (ECM) proteins, especially
collagen, to essentially plug holes in tissue.158 Angiotensin II increases the fibrotic
activity of myofibroblasts and promotes their differentiation.158 Thus, by reducing the
amount of angiotensin II in a tissue, ACE2 has antifibrotic effects.159 Fibrosis can be
connected to inflammation: when leukocytes secreting pro-inflammatory cytokines, the
amount of collagen present in wounded tissue is increased.158 It can also be connected to
thrombosis: a thromboembolism blocks blood, resulting in ischemia, followed by
necrosis and fibrosis.152 There are many benefits to maintaining tissue structure by shortterm organ scarring, such as the prevention of internal bleeding, the blocking of entry to
pathogens, and decreasing the likelihood of a second injury.158 However, if excessive
scarring occurs, as in fibrosis, organs lose functionality.158 The amount of functional
parenchymal tissue decreases as fibrosis increases.158 Also, fibrosis can cause organs to
lose their balance of elasticity that they rely on, as in pulmonary fibrosis, which increases
the elastic recoil of the lungs by causing them to make too much elastic fibers in their
ECM.160 Fibrosis can afflict any tissue capable of scarring, and several factors can lead
up to it (Figure 14).158
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Figure 14: Contributing factors to fibrosis and examples of organs that it can manifest in.
Excessive collagen formation without removing the stimuli causing it can lead to fibrosis
in the organs. ACE2 downregulation is a causal factor. Modified from Baues et al.,
2017.161
Pulmonary fibrosis decreases the productivity per breath, because with more
fibrotic tissue presence, less functional alveolar tissue is there to capitalize on the inhaled
air (Figure 15).158,162,163 Also, the elastic recoil of the lungs is increased due to the higher
elastin presence, which makes breathing more difficult as well as decreasing the forced
vital capacity, the volume of air that can be forcibly exhaled after a full breath.160,162
Pulmonary fibrosis is a major threat to survivors of serious lung injuries.164 The damages
to lung tissue caused by regular smoking, acute respiratory distress syndrome (ARDS),
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diffuse alveolar damage (DAD), and severe COVID-19 often force the lungs to repair
themselves via fibrosis.119,164–166 Pulmonary fibrosis tends to increase in severity over
time.167 The mean survival time after diagnosis with pulmonary fibrosis is 2 – 5 years,
and antifibrotic therapies and lung transplants are the main treatments.162,163,167,168

Figure 15: Diagram of normal lung tissue vs. pulmonary fibrosis. In A, healthy lung
tissue has a minimal fibroblast presence, healthy alveoli, a thin visceral pleura, and an
intact terminal bronchiole. In B, fibrotic lung tissue reveals higher fibroblast presence,
alveolar damages, a thicker visceral pleura, and a damaged terminal bronchiole. Image
from Fernandez and Eickelberg, 2012.163
Severe COVID-19 can damage many organs besides the lungs, some of which
include the kidneys, heart, digestive system, and liver.115,121 This means that fibrosis can
occur in any of these organs as well as a result of these damages.115,121 Many reports of
such fibroses have been documented in case studies and autopsy reports of severe
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COVID-19 patients, such as Spagnolo et al., 2020, as seen in Figure 16.119,121
Additionally, fibroses, especially pulmonary fibrosis, have also been documented in
survivors of severe COVID-19.88 Organ fibroses are also seen in ACE2 knockout models
and other ACE2 deficient disease states (Figure 17).121,169–171

Figure 16: Chest X-ray of a patient’s development of pulmonary fibrosis during severe
COVID-19. A shows small fibroses (white fibrous masses like the one indicated by the
arrow). B was taken 3 weeks later; many more fibroses are present. Image from Spagnolo
et al., 2020.119
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Figure 17: Renal fibrosis in mice with diabetic kidney injury with and without the gene
for ACE2. The brown dye indicates fibronectin, a marker of fibroblast activity. The left
image is of a mouse with a normal ACE2 gene; minimal fibrosis is present. The right
image is of an ACE2 knockout mouse; excessive fibrosis is visible. Image from Wong et
al., 2007.169
Since the advent of the COVID-19 pandemic, research on the relationship
between ACE2 and fibrosis has been amplified (Figure 18). The following meta-analysis
sorts a sample of sources reporting fibrosis by their organ in these three pathological
states (Table 4). Each bold number indicates the number of sources found that mentioned
an increase in fibrosis. Sources were obtained from PubMed and Google Scholar by
searching “ACE2 knockout fibrosis [organ],” “ACE2 fibrosis [organ],” or “COVID
fibrosis [organ].” The results were then screened according to their useful insights,
experimental results, and images. Sources that had no input relevant to this study were
not included. Three organs, the lungs, heart, and kidneys, were considered, but the effects
of ACE2 downregulation are felt by any tissue with this downregulation. No sources
associated ACE2 deficiency with decreasing fibrosis. One ACE2 knockout study
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indicated that no change was observed with regards to fibrosis in the heart.172 However, 2
other studies did observe fibrosis after knocking out ACE2.135,136

Figure 18: PubMed results for “ACE2 Fibrosis” by year. Research in this area was
slowly increasing until 2019, which saw a large increase in the amount of research in this
area due to COVID-19. Data taken on May 3, 2021.
Organ

ACE2 Knockout

Low ACE2

Severe COVID-19

3

7

6

Lungs
108–110

33,63,112–115,171

*

88,113,115,118–120

*

*

10
4

5
63,115,125–

Kidneys
122–124,169

115,121,127,132,134

*
127,129,131,170,173,174

Cardiovascular
System

2/3
135,136,172

8
*

*

*

33,63,76,114,115,137,140,173

4
*

31,115,121,141

*

Table 4: Meta-analysis data on the increase in fibrosis reported for ACE2 knockout
models, low ACE2 presence in tissues, and severe COVID-19. Each of these pathological
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conditions promotes fibrosis in each of the organs examined. *The smaller numbers
indicate the sources.
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RAS-based COVID-19 Treatments
The disruption of the RAS balance in severe COVID-19 provides a therapeutic
target, and throughout the course of this pandemic, several RAS-based treatments have
been proposed (Table 5). When something is present in too high amounts, as is
angiotensin II in severe COVID-19, it makes sense to reduce its presence. Conversely,
when there are insufficient amounts of something, as with ACE2 in severe COVID-19, it
makes sense to increase its presence. Almost every RAS-based treatment proposed for
severe COVID-19 attempts to either decrease angiotensin II levels or increase ACE2
levels.
Treatment

Effect

ACE2 Inhibitors

-

ADAM17 Enhancers

-

Renin Inhibitors

0

ACE Inhibitors

0

AT1R Blockers (ARBs)

0

Human Recombinant Soluble ACE2
+
(hrsACE2)
ADAM17 Inhibitors

+

Table 5: Proposed and developing RAS-based treatments for severe COVID-19. A
positive value indicates that the treatment helps reduce the symptoms of severe COVID19. A value of zero indicates little to no effect. A negative value indicates a harmful
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effect. ACE2 inhibitors and ADAM17 enhancers are predicted to be harmful based on the
patterns observed in this study, but no experimental data in the case of severe COVID-19
in humans is available, as it would be unethical to treat patients with medication likely to
be harmful.
Upon discovering that ACE2 was the receptor for SARS-CoV-2, some scientists
quickly assumed that inhibiting ACE2 would save critical patients and slow the spread of
the virus.175 Several scientists have warned against ACE2 inhibitor treatment in COVID19, indicating that they shift the balance of the RAS in favor of the classical angiotensin
II pathway.33,175 As shown in this paper, reducing ACE2 levels can be catastrophic.
ACE2 inhibitors are no longer being considered as a treatment for COVID-19. Most of
the other proposed RAS-based treatments work with the alternative RAS, rather than
against it.
Inhibitors of the classical RAS are popular prescription drugs used in the
treatment of hypertension.33,176 Renin inhibitors, ACE inhibitors, and AT1R blockers
(ARBs) all work to reduce the influence of angiotensin II.33,176,177 As such, they have
been examined as potential candidates for reducing the severity of severe COVID19.33,176,177 Earlier in the crisis, doctors were worried about renewing prescriptions of
these drugs, as they have been associated with ACE2 upregulation.176–178 The doctors did
not want to provide SARS-CoV-2 with more receptors to enter the cells of these high-risk
patients.176–178 Another set of doctors opposingly proposed that blocking the classical
RAS would weaken severe COVID-19 symptoms.176,177 Interestingly, many clinical
studies, including a large international cohort study by Morales et al., 2020, showed that
classical RAS inhibitors neither increased nor decreased risk of severe COVID-19.177,178
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One study interestingly found that ACE inhibitors and ARBs reduce the risk of COVID19, but not severe COVID-19.179 The reason for the widely reported ineffectiveness of
classical-RAS inhibitors in treating severe COVID-19 is currently unknown. Perhaps
they simply do not occur at the same level as the ACE2 downregulation in severe
COVID-19. Doctors currently recommend that these classical-RAS inhibiting drugs be
prescribed as normal, neither increasing nor decreasing prescriptions and/or
dosages.176,177
Human soluble recombinant ACE2 (hrsACE2) has been the most successful RASbased COVID-19 treatment.112 The idea behind it is that it both binds the spike protein on
SARS-CoV-2, blocking its entry into cells, and also helps to deplete angiotensin II,
lessening the effects of the classical RAS.112 Before the pandemic, hrsACE2 was already
in a clinical trial under the name APN01 as a treatment for various hypertensive,
pulmonary, cardiovascular, kidney, and cancerous diseases.180 Upon realization of its
potential as a treatment of severe COVID-19, APN01 studies skyrocketed in popularity.
It is now in phase 2 of clinical trials as a severe COVID-19 treatment and is showing very
promising results, aiding in several recoveries from the threshold of death.112 hrsACE2
has a half-life of 10 hours and is given intravenously twice daily.112,181 Several studies on
mice and people have revealed ACE2 treatment to reduce inflammation, thrombosis, and
fibrosis in treated organs (Table 6). Sources were obtained from PubMed and Google
Scholar by searching variations of “ACE2 treatment [organ] [symptom].” In addition to
sources found this way, certain sources from other sections of the meta-analysis also
discussed and/or performed ACE2 treatments, so they were included here as well.
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Organ

Less Inflammation

Less Thrombosis

Less Fibrosis

5

3

3

33,112,114,182,183

33,112,150

33,112,114

Lungs

3
Kidneys

3
0

124,128,129

124,129,174

Cardiovascular

1

1

System

114

150

0

Table 6: Meta-analysis data on the reduction of inflammation, thrombosis, and fibrosis
by ACE2 treatment by organ. Adding ACE2 to the lungs reduced inflammation,
thrombosis, and fibrosis. Adding ACE2 to the kidneys reduced inflammation and fibrosis.
Adding ACE2 to the cardiovascular system reduced inflammation and thrombosis. None
of the analyzed sources reported on whether ACE2 treatment affects kidney thrombosis
or cardiac (interstitial or otherwise) fibrosis. Note that ACE2 treatment is not necessarily
APN01 or even hrsACE2; often it was the ACE2 from the species being studied.
Another highly promising RAS-based treatment for severe COVID-19 is
ADAM17 inhibition.184 Severe COVID-19 is often associated with high levels of serum
ACE2, indicating that high ADAM17 activity is resulting in the cleavage of membrane
ACE2 and the disruption of the local RAS.79,84,184 By inhibiting ADAM17, less
membrane ACE2 is lost, and the tissue is less prone to ACE2 downregulation and the
harmful effects of excess angiotensin II.84,184 One paper naively recommended enhancing
ADAM17 rather than inhibiting it.185 The idea was to increase soluble ACE2 that would
block the viral spike proteins.185 However, this would almost certainly be harmful to the
organs experiencing the subsequent ACE2 downregulation.33,84 Though promising,
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ADAM17 inhibition is largely understudied compared to hrsACE2 in treating severe
COVID-19.184,185
Since COVID-19 and several other diseases are becoming more widely
understood to have RAS components as major causal factors, RAS-based treatments are
skyrocketing in research focus alongside the RAS itself. Typically, RAS imbalances are
in favor of the classical pathway, so treatments try to reduce that difference by promoting
the alternative RAS. The future is bright for these drugs.
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Conclusion
The COVID-19 pandemic has impacted the entire world, and vaccines are
becoming more widely available by the day in a valiant attempt to thwart it. SARS-CoV2, the virus behind the pandemic, targets ACE2, an enzyme present on cell surfaces
throughout the body with several critical functions in maintaining the integrity of tissues
as well as blood flow. In severe COVID-19, ACE2 is downregulated by viral entry and
increased activity of ADAM17, which causes the accumulation of its substrate,
angiotensin II. Angiotensin II then facilitates inflammation, thrombosis, and fibrosis in
the tissues and organs experiencing this downregulation.
The meta-analysis performed here elucidates the similarities between severe
COVID-19 and other ACE2 deficient states. Two promising but understudied treatments
of severe COVID-19 are based on countering the downregulation of ACE2. hrsACE2
(APN01) treatment, currently in phase 2 of clinical trials, directly adds soluble ACE2,
which both blocks the spike proteins on SARS-CoV-2 and reduces angiotensin II levels.
ADAM17 inhibition prevents ADAM17 from cleaving off membrane bound ACE2, thus
increasing the local ACE2 levels.
Although the current pandemic has been catastrophic in many regards, one
positive is that ACE2 research has become more mainstream. It is an incredible enzyme
with a very high therapeutic potential, but it is also complicated and was understudied
until recently. This sudden attention directed at ACE2 may herald treatments for
numerous pathologies beyond just severe COVID-19. The pandemic will hopefully end
soon, but the memories, wisdom, and insight gained from it must never be forgotten.
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